Skip to main content
Premium Trial:

Request an Annual Quote

Myriad Genetics, Positive Bio Partner on MDx Testing in India

NEW YORK (GenomeWeb) – Indian genomics testing firm Positive Bioscience announced today a partnership with Myriad Genetics to offer molecular diagnostic testing in that country. 

As part of the deal, Myriad will make available its tests covering nine cancers. They include BRACAnalysis to identify the risk of breast and ovarian cancer; Colaris to identify hereditary colorectal cancer; and myRisk, which assesses the risk of developing breast, prostate, endometrial, melanoma, pancreatic, colorectal, gastric, and ovarian cancer. 

Myriad also will offer its EndoPredict prognostic test for breast cancer, and Prolaris prognostic test for prostate cancer. All testing will be conducted at Myriad's laboratories in the US and Germany. 

"With our wide reach, thousands of Indians will instantly have access to world-class testing," Positive Bioscience CEO Samarth Jain said in a statement. "These tests will help patients by providing insights into potential healthcare challenges they may encounter and improve the quality of their lives." 

Financial and other terms of the deal were not disclosed.